Compare Expeditors International of Wshngtn Inc (EXPD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Sana Biotechnology Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $192.75 (market cap $25.18B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Expeditors International of Wshngtn Inc is far larger — about 30.1× Sana Biotechnology Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.84% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| EXPD | SANA | |
|---|---|---|
Market Cap | $25.18B | $836.71M |
Volume | 1,003,557 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $194.12 | $5.92 |
52-Week Low | $113.13 | $2.68 |
Typical Hold Time | 43 Days | — |
Enterprise Value | $24.72B | $749.96M |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expeditors International (EXPD) trades at $193.52, up 1.4% on the day, with a bullish technical signal from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $2.20. Revenue grew to $11.07B in 2025, while net income held steady at $810M. The company maintains strong profitability with a 42.6% ROE, though valuation multiples like the 28.2 P/E are elevated relative to historical norms.
Outlook is mixed; efficiency initiatives and airfreight demand support growth, but analyst consensus is cautious with a $179.43 price target below the current price. Key risks include reliance on global trade cycles and potential margin pressure. Upside depends on continued earnings beats and sustained freight market strength.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
